| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13D · 1 security · may seek to influence control | ||||||
|
Odyssey Therapeutics, Inc.
13D
ODTX · 67613T104
|
7.8% |
5/15/2026
Event 5/8/2026
|
||||
| Jeito II S.L.P. | 7.8% | |||||
| Jeito Capital SAS | 7.8% | |||||
| Rafaele Tordjman | 7.8% | |||||
| Sabine Dandiguian | 7.8% | |||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.